Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Prostate Adenocarcinoma 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 85Specimen Handling 66Prednisone 64Androgen Antagonists 59Abiraterone Acetate 58apalutamide 56Radiosurgery 52darolutamide 48Radiotherapy 47Leuprolide 47abiraterone 45Docetaxel 42Pluvicto 32Biopsy 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Radiation 30relugolix 28Surveys and Questionnaires 28gallium 68 PSMA-11 26Standard of Care 26pembrolizumab 25Goserelin 25Triptorelin Pamoate 24Gonadotropin-Releasing Hormone 23bicalutamide 22Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Buserelin × 1 year × Clear all
NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

NCT00936390 2026-03-06

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Radiation Therapy Oncology Group

Phase 3 Completed
1,538 enrolled 37 charts
Genitourinary

Prostatic Neoplasms

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Radiation Therapy Oncology Group

Phase 3 Completed
239 enrolled 38 charts
Genitourinary

Prostatic Neoplasms

NCT01492972 2025-09-04

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Proton Collaborative Group

Phase 3 Recruiting
192 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡